羟苯磺酸钙对糖尿病肾病3期患者hs-CRP、TNF-α的影响  

The Effects of Calcium Dobesilate on Serum hs-CRP and TNF-α in Patients with 3rd Stage of Diabetic Kidney Disease

作　　者：贾苗 谢玉贤 邱宏 JIA Miao;XIE Yuxian;QIU Hong(The People’s Hospital of SND,Suzhou 215129,China)

机构地区：[1]江苏省苏州市高新区人民医院,江苏苏州215129

出　　处：《中国医学创新》2018年第7期5-8,共4页Medical Innovation of China

基　　金：苏州高新区科技计划重点项目(2016Z008)

摘　　要：目的:探讨羟苯磺酸钙对糖尿病肾病(diabetic kidney disease,DKD)3期患者体内炎性因子hs-CRP、TNF-α的影响及对肾脏的保护作用。方法:选择本院2014年1月-2017年6月期间尿白蛋白肌酐比值(albumin to creatinie ratio,ACR)30~300μg/mg的DKD3期患者30例,按照随机数表法分为羟苯磺酸钙治疗组和DKD对照组,每组各15例。另外选择健康体检的正常人群15例作为健康对照组。检测三组患者的糖化血红蛋白、尿ACR、hs-CRP、α肿瘤坏死因子(tumor necrosis factor-α,TNF-α),治疗6个月后重复测定上述指标。结果:DKD3期患者hs-CRP、TNF-α水平显著高于健康对照组(P<0.05),经羟苯磺酸钙治疗6个月后,羟苯磺酸钙治疗组ACR、hs-CRP、TNF-α水平较DKD对照组明显下降(P<0.05)。结论:在控制血压、血糖在相同水平的基础上,羟苯磺酸钙可通过减少炎症因子,减轻炎症反应,减少尿蛋白的排泄从而延缓DKD3期的进展,保护肾脏。Objective:To explore the protective effect of calcium dobesilate on serum hs-CRP and TNF-αin patients with 3rd stage of diabetic kidney disease(DKD).Method:A total of 30 cases with 3rd stage of DKD in our hospital from January 2014 to June 2017 were randomly divided into Calcium Dobesilate group and DKD group according to table of random numbers,15 cases in each group.15 healthy volunteers were selected with same age,gender ratio as healthy control group.The levels of serum HbA1c,urinary ACR,hs-CRP,TNF-αof three groups were repeatedly measured after 6 months.Result:The levels of hs-CRP and TNF-αin 3rd stage of DKD were higher than those in healthy control group(P<0.05).After the treatment of Calcium Dobesilate for 6 months,the levels of urinary ACR,hs-CRP and TNF-αin Calcium Dobesilate group were significantly decreased than those in DKD group(P<0.05).Conclusion:Calcium Dobesilate might delay the development of 3rd stage of DKD and protect kidney through suppressing inflammation,reducing inflammatory factor and urinary protein excretion on the basis of the same values in blood pressure and blood glucose.

关 键 词：羟苯磺酸钙 超敏C反应蛋白 Α肿瘤坏死因子 糖尿病肾病 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]